Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04928846
Title A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AbbVie
Indications

lung non-small cell carcinoma

lung non-squamous non-small cell carcinoma

Therapies

Telisotuzumab vedotin

Docetaxel

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.